Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

NCT07234877 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: EORTC 2456-LCG-BTG
• Study Type: interventional
• Target: 158
• Locations: 8 countries
• Sites: 26

Brief Summary

This is a randomized, two-arm, comparative Phase II clinical trial designed to evaluate the difference in intracranial progression-free survival (iPFS) between two treatment strategies, assessed locally. Approximately 158 patients will be randomized in a 1:1 ratio. Will be included patients with pathology proven metastatic NSCLC without an actionable genomic alteration for which there is first line targeted treatment available and active asymptomatic brain metastasis (newly diagnosed or progressive). The primary objective is to compare iPFS between the two arms.

Conditions

Non Small Cell Lung Cancer

Keywords

Ivonescimab; Phase II study

Outcome Measures

Primary Outcomes (1)

• Intracranial progression-free survival based on local assessment using RANO-BM criteria

  Time interval between the date of randomization and the date of intracranial progression or neurological related death, whichever occurs first

  First at week 6 and week 12 (±1 week) post-randomization. Then every 12 weeks (±2 weeks) until intracranial progression or study discontinuation.

Secondary Outcomes (3)

• Overall survival

  Overall survival is defined as the time interval between the date of randomization and the date of death from any cause, assessed up to 4 years

• Intracranial PFS as per central review

  Intracranial PFS based on central assessment is defined as the time interval between the date of randomization and the date of intracranial progression or neurological related death, whichever occurs first, assessed up to 2 years

• Intracranial overall response rate (icORR), based on RANO-BM criteria as per local assessment

  The overall icORR is defined as the time interval between the date of randomization and the date of intracranial response, assessed up to 2 years

Study Arms (2)

Sequencing arm

EXPERIMENTAL

Patients will receive SRS/FSRT for all BM within ≤14 days from randomization, followed by 4 cycles of platinum-based chemotherapy combined with ivonescimab at 20 mg/kg every 3 weeks (Q3W). The systemic therapy will be followed by maintenance therapy with ivonescimab at 20 mg/kg plus pemetrexed (for patients with non-squamous NSCLC only) Q3W, for up to 2 years.

Drug: Ivonescimab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Paclitaxel-albumin; Radiation: Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT)

Systemic treatment alone arm

EXPERIMENTAL

Patients will receive 4 cycles of platinum-based chemotherapy combined with ivonescimab 20 mg/kg Q3W, followed by maintenance ivonescimab 20 mg/kg with pemetrexed (pemetrexed non-squamous only) Q3W for a maximum of 2 years.

Drug: Ivonescimab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Paclitaxel-albumin

Interventions

Ivonescimab DRUG

ivonescimab iv at 20 mg/kg every 3 weeks

Sequencing arm; Systemic treatment alone arm

Carboplatin DRUG

For adenocarcinoma : Carboplatin area under the curve of 5 mg/mL/min (AUC 5) IV with pemetrexed 500 mg/m2 IV on day 1 every 21 days (Q3W) for 4 cycles

Sequencing arm; Systemic treatment alone arm

Pemetrexed DRUG

For adenocarcinoma : Carboplatin area under the curve of 5 mg/mL/min (AUC 5) IV with pemetrexed 500 mg/m2 IV on day 1 every 21 days (Q3W) for 4 cycles

Sequencing arm; Systemic treatment alone arm

Paclitaxel DRUG

For squamous cell carcinoma: Carboplatin AUC 6 mg/mL/min IV/ paclitaxel IV 200 mg/m2 on day 1 every 21 days (Q3W) for 4 cycles (or 175 mg/m2 on D1 for Asian participant) Q3W for 4 cycles

Sequencing arm; Systemic treatment alone arm

Paclitaxel-albumin DRUG

For squamous cell carcinoma: Carboplatin AUC 6 mg/mL/min IV/ albumin-bound paclitaxel 100 mg/m2 on D1, 8 and 15 Q3W for 4 cycles

Sequencing arm; Systemic treatment alone arm

Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) RADIATION

Patients will receive SRS/FSRT for all BM within ≤14 days from randomization, followed by 4 cycles of platinum-based chemotherapy combined with ivonescimab at 20 mg/kg every 3 weeks (Q3W). The systemic therapy should be initiated within 7 to 10 days after the end of SRS/FSRT but no earlier than 3 days after its completion. This will be followed by maintenance therapy with ivonescimab at 20 mg/kg plus pemetrexed (for patients with non-squamous NSCLC only) Q3W, for up to 2 years.

Sequencing arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older
• ECOG PS \<= 2
• Patients with pathology proven metastatic NSCLC without an actionable genomic alteration for which there is first line targeted treatment approved by EMA and recommended by the ESMO guidelines.
• Asymptomatic or clinically symptomatic brain metastases defined as requiring a dose of steroids of maximum 4 mg equivalent dexamethasone per day for the last 7 days to control neurological symptoms. With the clinically oligosymptomatic further defined as having no indication for immediate localized brain therapy, including neurosurgery or radiotherapy. Patients with controlled seizures can be enrolled.
• Newly diagnosed brain metastasis with the following characteristics:
• newly diagnosed and untreated (except resected) brain metastases Note: if the neuronavigation MRI in the upfront SRS/FSRT arms shows \> 10 metastases, but the MRI used for enrolment showed 1-10 metastases, the patient will be still considered eligible.
• At least one metastasis should be at least 5x5 mm. In case of doubt on the diagnosis of brain metastasis, the lesion should not be irradiated but followed up.
• The largest metastasis must be \<10 mL in volume and \<30 mm in longest diameter (resected lesions would not count).
• The maximum cumulative volume of brain metastases must be \<30 mL (resected lesions would not count)
• Adequate Organ Function

You may not qualify if:

• Patients with oligometastatic NSCLC who are scheduled to receive radical local treatment to extra-cranial sites.
• Patients with contra-indications to brain MRI with gadolinium-based contrast agent.
• Active auto-immune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
• Patients with \>30 Gy of chest radiation therapy within 6 months prior to randomization; non-thoracic radiation therapy \>30Gy within 4 weeks prior to randomization, or palliative radiation therapy of ≤30 Gy within 7 days prior to randomization.
• Prior brain irradiation (including whole brain radiotherapy and SRS).
• Prior systemic treatment for metastatic NSCLC. Patients having received adjuvant or neoadjuvant chemotherapy or curative-intent chemoradiotherapy with or without PD-1/L1 inhibitors can be enrolled if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the development of metastatic disease.
• Major surgical procedures or serious trauma within 4 weeks prior to randomization or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator). Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to randomization.
• History of coagulopathy and/or clinically significant bleeding symptoms or risk within 4 weeks prior to randomization
• Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy
• History of serious cardiovascular, gastronintestinal, thromboembolic, neurological, or pulmonary conditions before randomization.
• History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to randomization

Sponsors & Collaborators

• Summit Therapeutics: collaborator
• European Organisation for Research and Treatment of Cancer - EORTC: lead

Study Sites (26)

Kepler University Hospital

Linz, 4021, Austria

Location

Medical University of Vienna

Vienna, 1090, Austria

Location

CLCC-Jean Perrin

Clermont-Ferrand, 63000, France

Location

Centre Leon Berard

Lyon, 69373, France

Location

Centre Antoine Lacassagne

Nice, 06189, France

Location

Institut Godinot

Reims, 51056, France

Location

Gustave Roussy

Villejuif, t 94805, France

Location

University Hospital Frankfurt -Senckenberg Institute of Neurooncology

Frankfurt am Main, 60590, Germany

Location

Universitaetsklinikum Jena

Jena, 07447, Germany

Location

Univ. Rostock-Zentrum für Radiologie mit Klinik und Poliklinik für Strahlentherapi

Rostock, 18058, Germany

Location

General hospital of Athens 'Alexandra'

Athens, 11528, Greece

Location

Diagnostic & Therapeutic Center of Athens Hygeia Hospital S.A.

Athens, 151 23, Greece

Location

Metropolitan Hospital

Athens, Greece

Location

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Brescia, Italy

Location

RCCS Ospedale San Raffaele

Milan, Italy

Location

Policlinico Universitario Campus Bio-Medico- Oncology Center

Roma, 00128, Italy

Location

Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola

Roma, 00186, Italy

Location

Azienda Sanitaria Universitaria Friuli Centrale (Ospedaliero Universitario "Santa Maria della Misericordia" )

Udine, 33100, Italy

Location

Academisch Ziekenhuis Maastricht

Maastricht, Netherlands

Location

Erasmuc Mc

Rotterdam, Netherlands

Location

UMC-Academisch Ziekenhuis Utrecht

Utrecht, Netherlands

Location

University Clinic Golnik

Golnik, 4204, Slovenia

Location

The Institute Of Oncology

Ljubljana, 1000, Slovenia

Location

Hospital Universitario de La Princesa

Madrid, 28006, Spain

Location

Hospital Universitario 12 De Octubre

Madrid, 28041, Spain

Location

Hospital Universitari Son Espases

Palma de Mallorca, 07120, Spain

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Carboplatin; Pemetrexed; Paclitaxel; Radiosurgery; Spermine Synthase

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Guanine; Hypoxanthines; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Dicarboxylic; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Diterpenes; Terpenes; Radiotherapy; Therapeutics; Stereotaxic Techniques; Neurosurgical Procedures; Surgical Procedures, Operative; Investigative Techniques; Alkyl and Aryl Transferases; Transferases; Enzymes; Enzymes and Coenzymes

Study Officials

• Lizza Hendriks, MD, PhD

  Maastricht UMC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

EORTC HQ

CONTACT

+32 2 774611; eortc@eortc.org

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2025
• First Posted: November 19, 2025
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): January 1, 2032
• Study Completion (Estimated): April 1, 2032
• Last Updated: June 4, 2026

Record last verified: 2026-06

Locations

IT (5); SL (2); FR (5); AU (2); NL (3); GR (3); DE (3); ES (3)